Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by Norinchukin Bank The

Norinchukin Bank The grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 448,700 shares of the medical research company's stock after buying an additional 6,593 shares during the period. Edwards Lifesciences accounts for 0.7% of Norinchukin Bank The's investment portfolio, making the stock its 27th biggest position. Norinchukin Bank The owned approximately 0.08% of Edwards Lifesciences worth $33,217,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $26,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Roble Belko & Company Inc acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $54,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,853 shares of company stock worth $5,163,062 over the last ninety days. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Down 3.2 %

Shares of NYSE:EW traded down $2.30 during mid-day trading on Monday, hitting $69.23. 3,767,362 shares of the company traded hands, compared to its average volume of 4,926,557. The firm has a market cap of $40.70 billion, a P/E ratio of 9.93, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The firm's 50 day simple moving average is $71.18 and its 200 day simple moving average is $70.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Evercore ISI reduced their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Truist Financial decreased their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $78.55.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.